Compare ACRS & KRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | KRUS |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 485.4M |
| IPO Year | 2015 | 2019 |
| Metric | ACRS | KRUS |
|---|---|---|
| Price | $3.97 | $34.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $10.09 | ★ $62.88 |
| AVG Volume (30 Days) | ★ 3.9M | 193.0K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 79.75 |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $282,763,000.00 |
| Revenue This Year | N/A | $16.80 |
| Revenue Next Year | N/A | $17.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.88 |
| 52 Week Low | $2.10 | $29.69 |
| 52 Week High | $6.60 | $80.84 |
| Indicator | ACRS | KRUS |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 42.00 |
| Support Level | $3.18 | $33.97 |
| Resistance Level | $4.67 | $41.99 |
| Average True Range (ATR) | 0.25 | 1.77 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 86.34 | 47.71 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.